These results suggest that PP2A modulation triggered apoptosis in multidrug-resistant CLL cells without engaging the classical Bax/Bak pathway, a known target of many proapoptotic anticancer therapies (44). The gene discussed is BAK1; the disease is B-cell chronic lymphocytic leukemia.